Last reviewed 2026-05-14 · How we verify

Tricerol (ETOFIBRATE)

Phase 2 active Small molecule

Tricerol (generic name: ETOFIBRATE) is a etofibrate drug. It is currently in Phase 2 development.

Tricerol works by inhibiting the enzyme acyl-CoA:cholesterol acyltransferase (ACAT), which is involved in the formation of cholesterol esters.

Tricerol (Etofibrate) is a small molecule etofibrate, a type of fibric acid derivative. It is used to treat high cholesterol and triglyceride levels. However, there is limited information available on its commercial status, approved indications, and pharmacokinetic properties. Further research is needed to determine its efficacy and safety profile. As a result, it is not widely used or recognized in the pharmaceutical industry.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ETOFIBRATE
Drug class	etofibrate
Modality	Small molecule
Therapeutic area	Metabolic
Phase	Phase 2

Mechanism of action

Think of it like a traffic cop: ACAT is like a traffic cop that helps cholesterol get into the bloodstream. Tricerol blocks this traffic cop, making it harder for cholesterol to get into the bloodstream and reducing the risk of heart disease.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tricerol CI brief — competitive landscape report
Tricerol updates RSS · CI watch RSS

Frequently asked questions about Tricerol

What is Tricerol?

Tricerol (ETOFIBRATE) is a etofibrate drug.

How does Tricerol work?

Tricerol works by inhibiting the enzyme acyl-CoA:cholesterol acyltransferase (ACAT), which is involved in the formation of cholesterol esters.

What is the generic name of Tricerol?

ETOFIBRATE is the generic (nonproprietary) name of Tricerol.

What drug class is Tricerol in?

Tricerol belongs to the etofibrate class. See all etofibrate drugs at /class/etofibrate.

What development phase is Tricerol in?

Tricerol is in Phase 2.

Drug class: All etofibrate drugs
Therapeutic area: All drugs in Metabolic

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing